US-based Nuvaira discovered a novel Nuvaira® Lung Denervation System for Medicare coverage purposes.
The Nuvaira's lung denervation system is developed to treat moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)risks in patients on optimal medical care.
Novel Denervation System consists of a specialised catheter which is inserted into the lungs. Radio waves are then used to destroy certain nerves thought to control airway constriction and mucus production.The new technology is proven to be safe and well-tolerated in people with COPD.
The therapeutic potential of Targeted Lung Denervation (TLD) will significantly meet medical need in patients at risk of COPD exacerbations, also called ‘lung attacks’, which represent the major driver of healthcare cost and poor clinical prognosis. The innovation of Nuvaira® Lung Denervation System would offer a much-needed solution to considerably improve patient outcomes in future years.
